Comparative efficacy of vitamin D status in reducing the risk of bladder cancer: A systematic review and network meta-analysis

Nutrition

Volumn 32, Issue 5, 2016, Pages 515-523

  Zhao, Yue ^a   Chen, Changhao ^b   Pan, Wenwei ^b   Gao, Ming ^c   He, Wang ^b   Mao, Ren ^a   Lin, Tianxin ^b   Huang, Jian ^b  

^a THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN MEMORIAL HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^c The People Hospital of Honghuagang District   (China)

Author keywords

Bladder cancer; Network meta analysis; Serum 25 hydroxyvitamin D; Systematic review; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; VITAMIN D; 25 HYDROXYERGOCALCIFEROL; ANTINEOPLASTIC AGENT; CALCIFEDIOL;

BLADDER CANCER; CANCER PREVENTION; CANCER RISK; COMPARATIVE EFFECTIVENESS; DISEASE ASSOCIATION; HUMAN; META ANALYSIS; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SYSTEMATIC REVIEW; VITAMIN BLOOD LEVEL; BAYES THEOREM; BLOOD; DIET THERAPY; EVIDENCE BASED MEDICINE; NETWORK META-ANALYSIS; NUTRITIONAL STATUS; PATHOPHYSIOLOGY; RISK; SEVERITY OF ILLNESS INDEX; URINARY BLADDER NEOPLASMS; VITAMIN D DEFICIENCY;

25-HYDROXYVITAMIN D 2; ANTICARCINOGENIC AGENTS; BAYES THEOREM; CALCIFEDIOL; EVIDENCE-BASED MEDICINE; HUMANS; NETWORK META-ANALYSIS; NUTRITIONAL STATUS; RISK; SEVERITY OF ILLNESS INDEX; URINARY BLADDER NEOPLASMS; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 84955618178     PISSN: 08999007     EISSN: 18731244     Source Type: Journal    
DOI: 10.1016/j.nut.2015.10.023     Document Type: Review

References (42)

1. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA: A Cancer Journal For Clinicians 2005, 55:74108.
2. Parkin D.M. The global burden of urinary bladder cancer. Scand J Urol Suppl 2008, 218:12-20.
3. Holick C.N., De Vivo I., Feskanich D., Giovannucci E., Stampfer M., Michaud D.S. Intake of fruits and vegetables, carotenoids, folate, and vitamins A, C, E, and risk of bladder cancer among women (United States). Cancer Causes Control 2005, 16:1135-1145.
4. Albert P.J., Proal A.D., Marshall T.G. Vitamin D: The alternative hypothesis. Autoimmun Rev 2009, 8:639-644.
5. Plum L.A., DeLuca H.F. Vitamin D, disease and therapeutic opportunities. Nat Rev Drug Discov 2010, 9:941-955.
6. Gallicchio L., Helzlsouer K.J., Chow W.H., Freedman D.M., Hankinson S.E., Hartge P., et al. Circulating 25-hydroxyvitamin D and the risk of rarer cancers: Design and methods of the Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am J Epidemiol 2010, 172:10-20.
7. Donkena K.V., Young C.Y. Vitamin D, sunlight and prostate cancer risk. Adv Prev Med 2011, 2011:281863.
8. Zhou W., Heist R.S., Liu G., Asomaning K., Neuberg D.S., Hollis B.W., et al. Circulating 25-hydroxyvitamin D levels predict survival in early-stage non-small-cell lung cancer patients. J Clin Oncol 2007, 25:479-485.
9. Goodwin P.J., Ennis M., Pritchard K.I., Koo J., Hood N. Prognostic effects of 25-hydroxyvitamin D levels in early breast cancer. J Clin Oncol 2009, 27:3757-3763.
10. Ng K., Meyerhardt J.A., Wu K., Feskanich D., Hollis B.W., Giovannucci E.L., et al. Circulating 25-hydroxyvitamin D levels and survival in patients with colorectal cancer. J Clin Oncol 2008, 26:2984-2991.
11. Drake M.T., Maurer M.J., Link B.K., Habermann T.M., Ansell S.M., Micallef I.N., et al. Vitamin D insufficiency and prognosis in non-Hodgkin's lymphoma. J Clin Oncol 2010, 28:4191-4198.
12. Mittal R.D., Manchanda P.K., Bhat S., Bid H.K. Association of vitamin-D receptor (Fok-I) gene polymorphism with bladder cancer in an Indian population. BJU Int 2007, 99:933-937.
13. Giovannucci E. The epidemiology of vitamin D and cancer incidence and mortality: a review (United States). Cancer Causes Control 2005, 16:83-95.
14. Mills E.J., Ioannidis J.P., Thorlund K., Schunemann H.J., Puhan M.A., Guyatt G.H. How to use an article reporting a multiple treatment comparison meta-analysis. JAMA 2012, 308:1246-1253.
15. Cipriani A., Higgins J.P., Geddes J.R., Salanti G. Conceptual and technical challenges in network meta-analysis. Ann Intern Med 2013, 159:130-137.
16. Lu G., Ades A.E. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 2004, 23:3105-3124.
17. Caldwell D.M., Welton N.J., Ades A.E. Mixed treatment comparison analysis provides internally coherent treatment effect estimates based on overviews of reviews and can reveal inconsistency. J Clin Epidemiol 2010, 63:875-882.
18. Caldwell D.M., Ades A.E., Higgins J.P. Simultaneous comparison of multiple treatments: Combining direct and indirect evidence. BMJ 2005, 331:897-900.
19. Jackson D., White I.R., Riley R.D. Quantifying the impact of between-study heterogeneity in multivariate meta-analyses. Stat Med 2012, 31:3805-3820.
20. Higgins J.P., Thompson S.G. Quantifying heterogeneity in a meta-analysis. Stat Med 2002, 21:1539-1558.
21. Ioannidis J.P., Patsopoulos N.A., Evangelou E. Uncertainty in heterogeneity estimates in meta-analyses. BMJ 2007, 335:914-916.
22. Egger M., Davey Smith G., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634.
23. Gorham E.D., Garland C.F., Garland F.C., Grant W.B., Mohr S.B., Lipkin M., et al. Optimal vitamin D status for colorectal cancer prevention: A quantitative meta analysis. Am J Prev Med 2007, 32:210-216.
24. Carpenter J.R. A method for presenting and comparing dose-response curves. J Pharmacol Methods 1986, 15:283-303.
25. Steenland K., Deddens J.A. A practical guide to dose-response analyses and risk assessment in occupational epidemiology. Epidemiology 2004, 15:63-70.
26. Afzal S., Bojesen S.E., Nordestgaard B.G. Low plasma 25-hydroxyvitamin D and risk of tobacco-related cancer. Clin Chem 2013, 59:771-780.
27. Amaral A.F., Mendez-Pertuz M., Munoz A., Silverman D.T., Allory Y., Kogevinas M., et al. Plasma 25-hydroxyvitamin D(3) and bladder cancer risk according to tumor stage and FGFR3 status: A mechanism-based epidemiological study. J Natl Cancer Inst 2012, 104:1897-1904.
28. Brinkman M.T., Buntinx F., Kellen E., Dagnelie P.C., Van Dongen M.C., Muls E., et al. Dietary intake of micronutrients and the risk of developing bladder cancer: Results from the Belgian case-control study on bladder cancer risk. Cancer Causes Control 2011, 22:469-478.
29. Brinkman M.T., Karagas M.R., Zens M.S., Schned A., Reulen R.C., Zeegers M.P. Minerals and vitamins and the risk of bladder cancer: Results from the New Hampshire Study. Cancer Causes Control 2010, 21:609-619.
30. Giovannucci E., Liu Y., Rimm E.B., Hollis B.W., Fuchs C.S., Stampfer M.J., et al. Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. J Natl Cancer Inst 2006, 98:451-459.
31. Mondul A.M., Weinstein S.J., Horst R.L., Purdue M., Albanes D. Serum vitamin D and risk of bladder cancer in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening trial. Cancer Epidemiol Biomarkers Prev 2012, 21:1222-1225.
32. Mondul A.M., Weinstein S.J., Mannisto S., Snyder K., Horst R.L., Virtamo J., et al. Serum vitamin D and risk of bladder cancer. Cancer Res 2010, 70:9218-9223.
33. Adorini L., Daniel K.C., Penna G. Vitamin D receptor agonists, cancer and the immune system: An intricate relationship. Curr Top Med Chem 2006, 6:1297-1301.
34. Thierry-Palmer M., Carlyle K.S., Williams M.D., Tewolde T., Caines-McKenzie S., Bayorh M.A., et al. Plasma 25-hydroxyvitamin D concentrations are inversely associated with blood pressure of Dahl salt-sensitive rats. J Steroid Biochem Mol Biol 1998, 66:255-261.
35. Thierry-Palmer M., Doherty A., Bayorh M.A., Griffin K. Dahl salt-sensitive rats excrete 25-hydroxyvitamin D into urine. J Nutr 2003, 133:187-190.
36. Chen F., Li Q., Yu Y., Yang W., Shi F., Qu Y. Association of vitamin C, vitamin D, vitamin E and risk of bladder cancer: A dose-response meta-analysis. Sci Rep 2015, 5:9599.
37. Liao Y., Huang J.L., Qiu M.X., Ma Z.W. Impact of serum vitamin D level on risk of bladder cancer: A systemic review and meta-analysis. Tumour Biol 2015, 36:1567-1572.
38. Looker A.C., Gunter E.W. Hypovitaminosis D in medical inpatients. N Engl J Med 1998, 339:344-345.
39. Malabanan A., Veronikis I.E., Holick M.F. Redefining vitamin D insufficiency. Lancet 1998, 351:805-806.
40. Bischoff-Ferrari H.A., Giovannucci E., Willett W.C., Dietrich T., Dawson-Hughes B. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr 2006, 84:18-28.
41. Holick M.F. High prevalence of vitamin D inadequacy and implications for health. Mayo Clin Proc 2006, 81:353-373.
42. Chapuy M.C., Preziosi P., Maamer M., Arnaud S., Galan P., Hercberg S., et al. Prevalence of vitamin D insufficiency in an adult normal population. Osteoporos Int 1997, 7:439-443.